Nika Pharmaceuticals Inc (OTC: NIKA) is a pre-revenue pharmaceutical development company that is developing generic drugs and dietary supplements for production and sale across multiple international territories. The company has not generated operating revenue as of its fiscal year ended December 31, 2025, and is funded entirely through related-party loans. As of December 31, 2025, CEO Dimitar Slavchev Savov had advanced the company a cumulative $205,164, and affiliated entity Nika Pharmaceuticals LTD (Bulgaria) had advanced $34,000, both non-interest bearing and due on demand. The company acquired four technologies in April 2024, covering three generic drugs in tablet form, MENTHYL VALERATE 0.06g, METAMIZOLE SODIUM 500mg, and VINPOCETINE 10mg, plus one dietary supplement, through its subsidiary Nika Europe Ltd. The company holds a 40% stake in Nika Europe Ltd. and operates under a 15-year cooperation agreement with Nika BioTechnology Inc. Auditors have issued a going concern qualification in the report accompanying the FY2025 financial statements.

Revenue model

No revenue has been reported for fiscal years ended December 31, 2025 or December 31, 2024. Operations are funded by related-party loans from the CEO and an affiliated Bulgarian entity. The stated future model involves production and sale of generic drugs and dietary supplements, with costs and net profits to be split equally with Nika BioTechnology Inc. under a cooperation agreement signed August 1, 2022.

Products and services

Three generic drug technologies in tablet form: MENTHYL VALERATE 0.06g, METAMIZOLE SODIUM 500mg, and VINPOCETINE 10mg, acquired April 12, 2024. One dietary supplement technology, also acquired April 2024. Six additional dietary supplements under exclusive rights agreement: Hypocholestin, Biodetoxin, Dry Boza, Fructin, Anthocylen C, and Silymaron. Prescription drug TNG and dietary supplements Physiolong and Carotilen under joint development with Nika BioTechnology Inc.

Customers and end markets

No customers or commercial sales disclosed in the FY2025 or FY2024 filings. End markets are pharmaceutical and dietary supplement consumers across Europe, Asia, Africa, South America, North America, and Australia per the exclusive rights agreement, though no sales have been made as of the filing date.

Value-chain role

Early-stage drug and supplement technology acquirer and developer. Nika Europe Ltd. is preparing construction of a pharmaceutical factory with manufacturing facilities for drugs in injection, tablet, and other forms. The company sits upstream of manufacturing and distribution, with no commercial production disclosed as of December 31, 2025.

Geographic exposure

Incorporated in the United States. Subsidiary Nika Europe Ltd. operates in Europe. Affiliated entity Nika Pharmaceuticals LTD is incorporated in Bulgaria. Exclusive rights cover Europe, Asia, Africa, South America, North America, and Australia per agreements disclosed in the 10-K filed 2026-03-25.

Source: SEC 10-K, filed 2026-03-25

Industry: Pharmaceutical Preparations Peers: Eli Lilly and Co